Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant ...
Tag: dermatology
Use of certain biologics or disease modifying antirheumatic drugs may be associated with cancer risk
1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with rheumatoid arthritis (RA) was associated with ...
Adjuvant dabrafenib and trametinib improve survival in stage III melanoma
1. After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free and metastasis-free survival compared to placebo in ...
Delgocitinib cream is effective and safe for the treatment of chronic hand eczema
1. More patients in the delgocitinib cream group reported clear or almost clear skin at week 16 in both the ...
Long-term survival improved with use of tebentafusp for metastatic uveal melanoma
1. Across a median follow-up of 48.5 months, usage of tebentafusp for patients with metastatic uveal melanoma was associated with ...
Bimekizumab safe and effective for treatment of moderate-to-severe hidradenitis suppurative
1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse ...
Radiation treatment for breast cancer may increase incidence of nonkeratinocyte skin cancer
1. Amongst a cohort of breast cancer survivors, those that were treated with radiation had a higher risk of developing ...
#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms
1. In this randomized controlled trial, treatment with JNJ-77242113 improved psoriasis symptoms as compared to a placebo. 2. JNJ-77242113 showed ...
Interleukin-23 receptor antagonist improves psoriasis symptoms
1. In this randomized controlled trial, treatment with JNJ-77242113 improved psoriasis symptoms as compared to a placebo. 2. JNJ-77242113 showed ...
Spesolimab may improve quality of life in patients with generalized pustular psoriasis flares
1. Efficacy of spesolimab appeared to be dose-dependent with high-dose spesolimab leading to a significantly longer time to GPP flare-up ...